Many are afraid to take hydroxychloroquine (HCQ) for COVID as they have been told it could kill them because of its effect on the heart. Are you worried about this?
It is a fact that HCQ, azithromycin (Z-Pak™), and other drugs can prolong the QT interval on the electrocardiogram (ECG)—see image below. This could make patients vulnerable to fatal changes in the heart’s rhythm (such as torsades de pointes or TdP). People with a rare condition called “congenital prolonged QT syndrome” are especially at risk.
You do not have to have an expensive ECG to check for this. It takes about 5 minutes with inexpensive new technology that fits in your pocket and can be used in your home (see below).
Victoria Police resort to violence Gaza Is Melbourne, Australia - Democracy Is Gone
Hundreds of millions of people have taken HCQ without ever worrying about this issue. Have we overlooked a serious problem for more than 50 years? A just-published article that reviews the medical literature concludes that, on the contrary, HCQ protects the heart.
In one case series of 251 COVID-19 patients treated with HCQ and azithromycin, extreme QT prolongation occurred in 23 percent. The HCQ was stopped; no deaths occurred. No reports of cardiac deaths were found in the review. Rather, “HCQ/azithromycin were uniformly found to substantially reduce cardiac mortality and also to decrease thrombosis, arrhythmia and cholesterol in treated patients.”
Warnings issued by FDA, CDC, the American Heart Association, and others have suppressed the use of potentially life-saving HCQ treatment. However, author Chadwick Prodromos, M.D., notes that warnings cite no specific study, and do not comment on whether actual deaths have occurred.
He concludes that: “HCQ decreases cardiac events. HCQ should not be restricted in use for COVID 19 patients because of fear of cardiac mortality.”
It is important to remember that COVID-19 itself can damage the heart, increasing the importance of early treatment.
Cardiologist Peter McCullough, M.D., M.P.H., of the Baylor Heart and Vascular Institute in Dallas, recommends HCQ and other measures for early treatment in a recent article in the American Journal of Medicine.
For information on 82 studies of HCQ, see https://c19study.com/.